• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

根治性膀胱切除术联合放化疗治疗肌层浸润性膀胱癌:治疗机构及社会人口统计学特征的影响

Radical Cystectomy Chemoradiation for Muscle-invasive Bladder Cancer: Impact of Treatment Facility and Sociodemographics.

作者信息

Haque Waqar, Verma Vivek, Butler E Brian, Teh Bin S

机构信息

Department of Radiation Oncology, CHI St Luke's Health, The Woodlands, TX, U.S.A.

Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, U.S.A.

出版信息

Anticancer Res. 2017 Oct;37(10):5603-5608. doi: 10.21873/anticanres.11994.

DOI:10.21873/anticanres.11994
PMID:28982876
Abstract

BACKGROUND

The present study sought to compare the differences in practice patterns, as well as clinical outcomes for patients with muscle-invasive bladder cancer undergoing treatment with either radical cystectomy (RC) or concurrent chemoradiaiton (CRT).

PATIENTS AND METHODS

The National Cancer Data Base (NCDB) was queried for patients diagnosed with T2/T3/T4aN0M0 bladder cancer, between 2004-2013, that received definitive treatment with either RC or CRT.

RESULTS

16,960 patients met the inclusion criteria; 1,450 (8.5%) underwent CRT, while 15,510 (91.5%) were treated with RC. Patients undergoing CRT were older, more likely to be female, African American, received treatment at an academic facility, and lived <20 miles of the treatment facility. CRT was associated with worse median OS (32.8 months vs. 36.1 months; p=0.0004).

CONCLUSION

Older patients are more likely to undergo bladder preservation therapy, while those living farther away from treatment facilities are less likely to under CRT.

摘要

背景

本研究旨在比较接受根治性膀胱切除术(RC)或同步放化疗(CRT)治疗的肌层浸润性膀胱癌患者的治疗模式差异以及临床结局。

患者与方法

查询国家癌症数据库(NCDB)中2004年至2013年间被诊断为T2/T3/T4aN0M0膀胱癌且接受了RC或CRT确定性治疗的患者。

结果

16960例患者符合纳入标准;1450例(8.5%)接受了CRT,而15510例(91.5%)接受了RC治疗。接受CRT的患者年龄更大,更可能为女性、非裔美国人,在学术机构接受治疗,且居住在距治疗机构<20英里的地方。CRT与更差的中位总生存期相关(32.8个月对36.1个月;p=0.0004)。

结论

老年患者更可能接受膀胱保留治疗,而居住在距治疗机构较远的患者接受CRT的可能性较小。

相似文献

1
Radical Cystectomy Chemoradiation for Muscle-invasive Bladder Cancer: Impact of Treatment Facility and Sociodemographics.根治性膀胱切除术联合放化疗治疗肌层浸润性膀胱癌:治疗机构及社会人口统计学特征的影响
Anticancer Res. 2017 Oct;37(10):5603-5608. doi: 10.21873/anticanres.11994.
2
Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database.八旬膀胱癌肌层浸润性癌患者的治疗模式和总生存结局:国家癌症数据库分析。
J Urol. 2018 Feb;199(2):416-423. doi: 10.1016/j.juro.2017.08.086. Epub 2017 Aug 24.
3
Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.美国肌肉浸润性膀胱癌潜在治愈疗法的使用:来自国家癌症数据库的结果。
Eur Urol. 2013 May;63(5):823-9. doi: 10.1016/j.eururo.2012.11.015. Epub 2012 Nov 19.
4
Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.接受根治性膀胱切除术或膀胱保留治疗的肌层浸润性膀胱癌患者的当代使用趋势和生存结果。
Cancer. 2017 Nov 15;123(22):4337-4345. doi: 10.1002/cncr.30900. Epub 2017 Jul 25.
5
Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder.局部肌层浸润性膀胱癌行三联疗法与根治性膀胱切除术的疗效比较。
Eur Urol. 2017 Oct;72(4):483-487. doi: 10.1016/j.eururo.2017.03.038. Epub 2017 Apr 12.
6
Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.联合治疗浸润性膀胱癌保膀胱的长期疗效:MGH 经验。
Eur Urol. 2012 Apr;61(4):705-11. doi: 10.1016/j.eururo.2011.11.010. Epub 2011 Nov 12.
7
Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder.膀胱癌小细胞癌患者的治疗模式和生存结果。
Eur Urol Focus. 2018 Dec;4(6):900-906. doi: 10.1016/j.euf.2017.09.001. Epub 2017 Sep 14.
8
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.保留膀胱的三联疗法治疗肌层浸润性膀胱癌患者的长期疗效:马萨诸塞州综合医院经验的更新分析。
Eur Urol. 2017 Jun;71(6):952-960. doi: 10.1016/j.eururo.2016.12.020. Epub 2017 Jan 9.
9
Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer.比较肌层浸润性膀胱癌行放化疗与根治性膀胱切除术的生存预后的倾向评分匹配分析。
BJU Int. 2018 May;121(5):745-751. doi: 10.1111/bju.14109. Epub 2018 Jan 22.
10
Pathology-based risk stratification of muscle-invasive bladder cancer patients undergoing cystectomy for persistent disease after induction chemoradiotherapy in bladder-sparing approaches.在保留膀胱的治疗方法中,接受诱导放化疗后疾病持续存在而行膀胱切除术的肌层浸润性膀胱癌患者,基于病理学的风险分层。
BJU Int. 2012 Sep;110(6 Pt B):E203-8. doi: 10.1111/j.1464-410X.2011.10874.x. Epub 2012 Jan 30.

引用本文的文献

1
Treatment trends of muscle invasive bladder cancer: Evidence from the Surveillance, Epidemiology, and End Results database, 1988 to 2013.肌层浸润性膀胱癌的治疗趋势:来自监测、流行病学和最终结果数据库(1988年至2013年)的证据
Asian J Urol. 2023 Jan;10(1):9-18. doi: 10.1016/j.ajur.2021.10.002. Epub 2021 Nov 2.
2
Prognostic Factors for Bladder Cancer Patients in Malaysia: A Population-Based Study.马来西亚膀胱癌患者的预后因素:一项基于人群的研究。
Int J Environ Res Public Health. 2022 Mar 4;19(5):3029. doi: 10.3390/ijerph19053029.
3
Survival and Characteristics of Bladder Cancer: Analysis of the Malaysian National Cancer Registry.
膀胱癌的生存与特征:马来西亚国家癌症登记处分析。
Int J Environ Res Public Health. 2021 May 14;18(10):5237. doi: 10.3390/ijerph18105237.
4
TOP2A and CENPF are synergistic master regulators activated in cervical cancer.TOP2A 和 CENPF 是协同激活的宫颈癌主要调控因子。
BMC Med Genomics. 2020 Oct 6;13(1):145. doi: 10.1186/s12920-020-00800-2.
5
The perils of using registry data to compare the survival and cost of radical cystectomy and trimodality therapy in bladder cancer.使用登记数据比较膀胱癌根治性膀胱切除术和三联疗法的生存率及成本的风险。
Transl Androl Urol. 2019 Dec;8(Suppl 5):S533-S537. doi: 10.21037/tau.2019.12.35.
6
Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma.接受手术切除的胰腺腺癌患者新辅助化疗或放化疗疗效的长期预后
J Gastrointest Oncol. 2019 Oct;10(5):918-927. doi: 10.21037/jgo.2019.07.02.
7
National Cancer Database report of nonmetastatic esophageal small cell carcinoma.国家癌症数据库报告:非转移性食管小细胞癌。
Cancer Med. 2018 Dec;7(12):6365-6373. doi: 10.1002/cam4.1712. Epub 2018 Nov 6.
8
National Cancer Database Comparison of Radical Cystectomy vs Chemoradiotherapy for Muscle-Invasive Bladder Cancer: Implications of Using Clinical vs Pathologic Staging.国家癌症数据库比较肌层浸润性膀胱癌根治性膀胱切除术与放化疗:临床分期与病理分期的应用意义。
Cancer Med. 2018 Nov;7(11):5370-5381. doi: 10.1002/cam4.1684. Epub 2018 Oct 10.
9
Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base.不可切除肝内胆管癌的化疗联合放疗与单纯化疗:来自国家癌症数据库的实践模式与结果
J Gastrointest Oncol. 2018 Jun;9(3):527-535. doi: 10.21037/jgo.2018.01.15.
10
Utilization of intensity modulated radiation therapy for anal cancer in the United States.美国调强放射治疗在肛管癌中的应用
J Gastrointest Oncol. 2018 Jun;9(3):466-477. doi: 10.21037/jgo.2018.03.03.